EUVIMEDEUVIMED entdecken
Crossref

Discovery of WDR5–MLL1 and HDAC Dual-Target Inhibitors for the Treatment of Acute Myeloid Leukemia

Guanlu Long, Xianghan Wang, Xin Chen, Sai Ma, Liangkui Sun, Zhengyu Jiang iD, Qidong You iD, Xiaoke Guo iD

Journal of Medicinal Chemistry · 2025

DOI: 10.1021/acs.jmedchem.4c01720 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Guanlu Long und 7 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Key Laboratory of Drug Design and Optimization and State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009…. Hauptthemen laut MEDLINE: Myeloid-Lymphoid Leukemia Protein, Histone Deacetylase Inhibitors, Leukemia, Myeloid, Acute, Histone-Lysine N-Methyltransferase. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: Natural Science Foundation of Jiangsu Province, Government of Jiangsu Province, Fundamental Research Funds for the Central Universities.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeting the WDR5-MLL1 protein-protein interaction (PPI) is considered to be an effective approach for the treatment of MLL-rearranged leukemia. However, interfering with WDR5-MLL1 PPI reduces methylated H3K4 levels and induces a decline in acetylated H3 levels, which may contribute to the suboptimal cellular efficacy of WDR5 inhibitors. We observed that cotreatment with WDR5-MLL1 PPI and HDAC inhibitors augmented the antiproliferative effect in MV-4-11 cells. Thus, a series of dual-target inhibitors was developed by merging the pharmacophores of the WDR5 and HDAC inhibitors. Among the developed inhibitors, compound 32d displayed an 89-fold increase in antiproliferative efficacy and induced potent cell apoptosis by impeding the DNA damage repair signaling pathway. Furthermore, the administration of 30 mg/kg of compound 32d was well tolerated, inhibiting MV-4-11 xenograft growth by 87.1%. Our investigation established the therapeutic effectiveness of the developed WDR5-MLL1/HDAC dual-target inhibitor against acute myeloid leukemia, providing a valuable tool for further exploration of crosstalk between the two targets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myeloid-Lymphoid Leukemia ProteinHistone Deacetylase InhibitorsLeukemia, Myeloid, AcuteHistone-Lysine N-MethyltransferaseIntracellular Signaling Peptides and ProteinsCell ProliferationAntineoplastic AgentsHumansAnimalsCell Line, TumorMiceApoptosisDrug DiscoveryStructure-Activity RelationshipXenograft Model Antitumor Assays

Substanzen

WDR5 protein, humanMyeloid-Lymphoid Leukemia ProteinKMT2A protein, humanHistone Deacetylase InhibitorsHistone-Lysine N-MethyltransferaseIntracellular Signaling Peptides and ProteinsAntineoplastic Agents

Autor:innen und Institutionen

  • Jiangsu Key Laboratory of Drug Design and Optimization and State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China.
  • Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.

ORCID-Profile: Zhengyu Jiang, Qidong You, Xiaoke Guo

Förderung

  • Natural Science Foundation of Jiangsu Province
  • Government of Jiangsu Province
  • Fundamental Research Funds for the Central Universities
  • National Natural Science Foundation of China

Zitieren

APA

Long, G., Wang, X., Chen, X., Ma, S., Sun, L., Jiang, Z., You, Q., & Guo, X. (2025). Discovery of WDR5–MLL1 and HDAC Dual-Target Inhibitors for the Treatment of Acute Myeloid Leukemia. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c01720

Vancouver

Long G, Wang X, Chen X, Ma S, Sun L, Jiang Z, et al. Discovery of WDR5–MLL1 and HDAC Dual-Target Inhibitors for the Treatment of Acute Myeloid Leukemia. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c01720

BibTeX
@article{Long2025,
  author = {Long, Guanlu and Wang, Xianghan and Chen, Xin and Ma, Sai and Sun, Liangkui and Jiang, Zhengyu and You, Qidong and Guo, Xiaoke},
  title = {Discovery of WDR5–MLL1 and HDAC Dual-Target Inhibitors for the Treatment of Acute Myeloid Leukemia},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  doi = {10.1021/acs.jmedchem.4c01720}
}
Kostenlos starten →